60399-02-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Hydroxy-N-methylbenzylamine hydrochloride is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic effects.
Used in Organic Chemistry:
As a building block in organic chemistry, 2-Hydroxy-N-methylbenzylamine hydrochloride is used in the synthesis of biologically active molecules, playing a crucial role in the creation of compounds with specific biological functions and properties.
Used in Medicinal Applications:
2-Hydroxy-N-methylbenzylamine hydrochloride is used as an antihistaminic drug, leveraging its properties to counteract the effects of histamine, which is involved in various allergic reactions and inflammatory processes.
Used in Disease and Disorder Treatment:
2-HYDROXY-N-METHYLBENZYLAMINE HYDROCHLORIDE has demonstrated potential in treating a range of diseases and disorders, making it a valuable asset in the search for novel therapeutic agents and treatments in the medical field.

InChI:InChI=1/C8H11NO.ClH/c1-9-6-7-4-2-3-5-8(7)10;/h2-5,9-10H,6H2,1H3;1H

Upstream product

• 3117-65-5 2-(methyliminomethyl)phenol 
• 107910-69-0 N-salicylidene methylamine 
• 90-02-8 salicylaldehyde 
• 74-89-5 methylamine 
• 593-51-1 methylamine hydrochloride 
• 108-95-2 phenol 
• 89-95-2 2-methyl-benzyl alcohol 
• 932-30-9 2-Hydroxybenzylamine 
• 5211-15-4 N-(2-Hydroxy-benzyl)-N-methyl-formamid 

Downstream Products

• 229487-00-7 3-benzyloxycarbonylamino-N-(2-hydroxy-benzyl)-N-methyl-succinamic acid methyl ester 
• 74-89-5 methylamine 
• 309965-23-9 4-Nitrophenyl N-(2-hydroxybenzyl)-N-methylcarbamate 
• 90007-13-9 N-nitrozo(o-hydroxybenzyl)methylamine 
• 5635-98-3 2-(methoxymethyl)phenol 

Relevant academic research and scientific papers

Targeting Bacterial Nitric Oxide Synthase with Aminoquinoline-Based Inhibitors

Nitric oxide is produced in Gram-positive pathogens Bacillus anthracis and Staphylococcus aureus by the bacterial isoform of nitric oxide synthase (NOS). Inhibition of bacterial nitric oxide synthase (bNOS) has been identified as a promising antibacterial strategy for targeting methicillin-resistant S. aureus [Holden, J. K., et al. (2015) Chem. Biol. 22, 785-779]. One class of NOS inhibitors that demonstrates antimicrobial efficacy utilizes an aminoquinoline scaffold. Here we report on a variety of aminoquinolines that target the bacterial NOS active site, in part, by binding to a hydrophobic patch that is unique to bNOS. Through mutagenesis and crystallographic studies, our findings demonstrate that aminoquinolines are an excellent scaffold for further aiding in the development of bNOS specific inhibitors.

Novel highly selective peroxisome proliferator-activated receptor δ (PPARδ) modulators with pharmacokinetic properties suitable for once-daily oral dosing

Optimization of benzamide PPARδ modulator 1 led to (E)-6-(2-((4-(furan-2-yl)-N-methylbenzamido)methyl)phenoxy)-4-methylhex-4-enoic acid (18), a potent selective PPARδ modulator with significantly improved exposure in multiple species following oral administration.

PESTICIDAL COMPOUNDS

A method of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effect

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).

4-Phenyl tetrahydroisoquinolines as dual norepinephrine and dopamine reuptake inhibitors

Novel 4-phenyl tetrahydroisoquinolines that inhibit both dopamine and norepinephrine transporters were designed and prepared. In this Letter, we describe the synthesis, in vitro activity and associated structure-activity relationships of this series. We also report the ex vivo NET occupancy of a representative compound, 41.

Synthesis of 3,4-dihydro-2H-1,3-benzoxazines by condensation of 2-hydroxyaldehydes and primary amines: Application to the synthesis of hydroxy-substituted and deuterium-labeled compounds

We report the synthesis of several substituted 3,4-dihydro-2H-1,3- benzoxazines by simple ring closure of 2-hydroxybenzylamines with paraformaldehyde. The facile synthesis of the benzylamine precursors from commercially available salicylaldehyde derivativ

Selective mono-N-alkylation of 3-amino alcohols via chelation to 9-BBN

(Chemical Equation Presented) A method for selective mono-N-alkylation of amino alcohols is introduced. This method relies on formation of a stable chelate with 9-BBN, which serves in the dual roles of protecting and activating the amine group. Three prot

N-Nitrosobenzylmethylamine hydroxylation and coumarin 7-hydroxylation: Catalysis by rat esophageal microsomes and cytochrome P450 2A3 and 2A6 enzymes

N-Nitrosobenzylmethylamine (NBzMA) is a potent and selective esophageal carcinogen in the rat and may be a causative agent for human esophageal cancer. This nitrosamine, like most, must be metabolically activated to exert its carcinogenic potential. NBzMA may be metabolized by P450-catalyzed methyl or methylene hydroxylation; the latter is believed to be the activation pathway. The sensitivity of the esophagus to NBzMA-induced tumorigenesis is believed to be due, at least in part, to the presence of efficient P450 catalysts in this tissue. However, while it was reported almost 20 years ago that the rat esophagus catalyzes the methylene hydroxylation of NBzMA, the P450 that catalyzes this reaction has yet to be identified. We report here that human P450 2A6 and the closely related extrahepatic rat enzyme P450 2A3 both efficiently catalyze NBzMA methylene hydroxylation, characterized as benzaldehyde formation. The catalytic efficiency of P450 2A3 in this reaction was 3-fold greater than that of P450 2A6, 7.6 (K(m) = 0.63 ± 0.18 μM and the V(max) = 4.8 nmol min-1 nmol of P450-1) versus 2.3 (K(m) = 6.7 ± 2.9 μM and the V(max) = 15.7 nmol min-1 nmol of P450-1), respectively. Both enzymes catalyzed methylene hydroxylation at least 4-fold more efficiently than methyl hydroxylation. In addition, P450 2A6, but not P450 2A3, catalyzed benzyl ring hydroxylation, generating N-(p-hydroxybenzyl)methylamine. The identity of this metabolite was confirmed by synthesis of a standard and LC/MS and LC/MS/MS analysis. P450 2A6 is an efficient coumarin 7-hydroxylase, and we report here that P450 2A3 is an equally good catalyst of this reaction (K(m) = 1.7 ± 0.41 μM and V(max) = 1.7 ± 0.08 nmol min-1 nmol of P450- 1). Rat esophageal microsomes (REM), like P450 2A3, were efficient catalysts of NBzMA methylene hydroxylation. However, in contrast to P450 2A3, the major product of this reaction was the product of benzaldehyde oxidation, benzoic acid. Antibody to the closely related mouse P450, 2A5, did not inhibit REM- catalyzed NBzMA metabolism, and most importantly, REM did not catalyze the 7- hydroxylation of coumarin. Therefore, P450 2A3 does not appear to be the P450 in the rat esophagus responsible for catalyzing the methylene hydroxylation of NBzMA.

An alternative synthesis of a potent GPIIb/IIIa receptor antagonist

A key intermediate to SB-214857 was prepared via an oxidative cyclization of a hydroquinone with a flanking aspartate side chain using Fremy's salt.

3,4-Dihydro-3-methyl-6-nitro-2H-1,3-benzoxazin-2-one, a Reagent for Labeling p-Nitrophenyl Esterases with a Chromophoric Reporter Group - Synthesis and Reaction with Chymotrypsin

We reported the synthesis of 3,4-dihydro-3-methyl-6-nitro-2H-1,3-benzoxazin-2-one (DMNB), a close structural anlogue of p-nitrophenyl dimethylcarbamate.DMNB is unstable in aqueous solution when exposed to light, but is stable in the dark.The compound reac